MicuRx Tests Oral/IV Versions of its Anti-Infective in US Trial

MicuRx Pharma, a US-China anti-infectives company, has begun a US Phase I trial to test the oral and IV formulations of its novel antimicrobial agent MRX-4. MRX-4 is aimed at treating Gram-positive infections including drug-resistant strains. MRX-4 is an oral prodrug form of MRX-1, which is currently in China Phase III trials as a treatment for complicated skin infections. Both forms are expected to be effective against methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococci (VRE). More details.... Share this with colleagues: // //